Protocol Ledger

NCT05082519 · Phase II · RECRUITING

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Interventional Phase II clinical trial protocol NCT05082519 sponsored by Etan Orgel in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-12 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05082519
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05082519
Protocol FieldVerified Registry Value
NCT IdentifierNCT05082519
Consolidated Lead SponsorEtan Orgel
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2022-03-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI